Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback